GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Total Liabilities History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹14,925 Cr | ₹13,309 Cr | ₹17,566 Cr | ₹15,397 Cr | ₹14,069 Cr |
What is the latest Total Liabilities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Total Liabilities |
|---|---|
| Mar2025 | ₹14,925 Cr |
| Mar2024 | ₹13,309 Cr |
| Mar2023 | ₹17,566 Cr |
| Mar2022 | ₹15,397 Cr |
| Mar2021 | ₹14,069 Cr |
How is Total Liabilities of GLENMARK PHARMACEUTICALS Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹14,925 Cr | 12.15 | |
| Mar2024 | ₹13,309 Cr | -24.23 | |
| Mar2023 | ₹17,566 Cr | 14.08 | |
| Mar2022 | ₹15,397 Cr | 9.44 | |
| Mar2021 | ₹14,069 Cr | - | |
Compare Total Liabilities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹56,634.7 Cr | -1.6% | 2.8% | 26.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹415,073.0 Cr | -0% | -3.2% | -5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹175,657.0 Cr | 4% | 5.2% | 11.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹134,121.0 Cr | 3.6% | 7% | 22% | Stock Analytics | |
| CIPLA | ₹118,431.0 Cr | -3.5% | -1.5% | -2.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹100,944.0 Cr | -3.2% | -3.3% | -10.6% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | -1.6% |
2.8% |
26.6% |
| SENSEX | -2.6% |
-1.3% |
7.2% |
You may also like the below Video Courses